Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer

被引：19
|
作者：
Lou, Emil [1 ]
Vogel, Rachel I. [2 ]
Hoostal, Spencer [3 ]
Klein, Molly [4 ]
Linden, Michael A. [4 ]
Teoh, Deanna [2 ]
Geller, Melissa A. [2 ]
机构：
[1] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Box 736 UMHC, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Obstet & Gynecol, Div Gynecol Oncol, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA
[4] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
来源：
JAMA ONCOLOGY | 2019年 / 5卷 / 08期
基金：
美国国家卫生研究院;
关键词：
PERCENTAGE;
D O I：
10.1001/jamaoncol.2019.1943
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This study assesses tumor-stroma proportion and compares this finding with the development of resistance to platinum-based chemotherapy in women newly diagnosed with ovarian carcinoma.
引用
收藏
页码：1222 / 1224
页数：3
相关论文
共 50 条
  • [1] Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian Cancer
    Lou, Emil
    Clemente, Valentino
    Grube, Marcel
    Svedbom, Axel
    Nelson, Andrew C.
    Blome, Freya
    Staebler, Annette
    Kommoss, Stefan
    Bazzaro, Martina
    JAMA NETWORK OPEN, 2024, 7 (02) : e240407
  • [2] NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer
    Konrad, Sarah M.
    Schwamborn, Kristina
    Krueger, Achim
    Honert, Katja
    Schmitt, Manfred
    Hellmann, Daniela
    Schmalfeldt, Barbara
    Meindl, Alfons
    Kiechle, Marion
    Quante, Anne S.
    Brambs, Christine
    Grill, Sabine
    Ramser, Juliane
    BIOMARKERS IN MEDICINE, 2022, 16 (14) : 1029 - 1041
  • [3] VIMENTINE AS A PREDICTIVE MARKER OF PLATINUM-BASED CHEMOTHERAPY IN OVARIAN CANCER PATIENTS
    Bogush, T.
    Dudko, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1408 - 1408
  • [4] MicroRNA tumor expression patterns associated with resistance to platinum-based chemotherapy and survival in patients with ovarian cancer
    Eitan, R.
    Kushnir, M.
    Yanai, G. Lithwick
    Melamed, N.
    Sabah, G.
    Glezerman, M.
    Hod, M.
    Levavi, H.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S141 - S141
  • [5] Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer
    Yang, Ling
    Xie, Hong-Jian
    Li, Ying-Ying
    Wang, Xia
    Liu, Xing-Xin
    Mai, Jia
    ONCOLOGY REPORTS, 2022, 47 (04)
  • [6] Development and Validation of a Predictive Model for Resistance to Platinum-Based Chemotherapy in Patients with Ovarian Cancer through Proteomic Analysis
    Mo, Yanqun
    Liu, Junliang
    Hu, Yi
    Peng, Xiaotong
    Liu, Huining
    JOURNAL OF PROTEOME RESEARCH, 2024, 23 (10) : 4648 - 4657
  • [7] Related Clinical Factors of Platinum-Based Chemotherapy Resistance in Patients with Epithelial Ovarian Cancer
    Xiong, Zhuo
    Ha, Chunfang
    Li, Ruyue
    Wu, Mingyong
    Wei, Meng
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2024, 89 (06) : 469 - 477
  • [8] Tumor-stroma type and tumor-stroma ratio predict neoadjuvant chemotherapy response in breast cancer
    Okcu, Oguzhan
    Ozturk, Cigdem
    Yalcin, Anil Can
    Sen, Bayram
    Yalcin, Nazlican
    Hacihasanoglu, Ezgi
    Aydin, Esra
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2025, 71 (02):
  • [9] Predicting Ovarian Cancer Patients' Clinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures
    Yu, Kun-Hsing
    Levine, Douglas A.
    Zhang, Hui
    Chan, Daniel W.
    Zhang, Zhen
    Snyder, Michael
    JOURNAL OF PROTEOME RESEARCH, 2016, 15 (08) : 2455 - 2465
  • [10] Influence of platinum-based chemotherapy on disseminated tumor cells in patients with primary ovarian cancer.
    Wimberger, P.
    Kimmig, R.
    Schulte, A.
    Scheulen, M. E.
    Kasimir-Bauer, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 272S - 272S
12345